Clinical Trials

665 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07046923 2026-06-02

A Study of LY4175408 in Participants With Advanced Cancer

BreastGynecologicThoracic

240 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05533697 2026-05-28

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Neoplasm Metastasis

NCT04534205 2026-05-22

AHEAD-MERIT

Phase 2/3 Recruiting

350 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05614739 2026-05-19

FORAGER-1

535 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT04977453 2026-05-15

Keynote B59

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT06697301 2026-05-08

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Phase 2/3 Recruiting

740 enrolled

Neoplasm Metastasis

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06270706 2026-04-20

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

124 enrolled

Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

118 enrolled

Dermatologic

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT07283731 2026-04-17

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

20 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT07262619 2026-04-08

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

160 enrolled

Gynecologic

Turcot syndrome, Neoplasm Metastasis, Endometrial Neoplasms

NCT04443088 2026-03-18

KEYNOTE-E12

78 enrolled

Neoplasm Metastasis, Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT07176312 2026-02-04

ZANGEA

80 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05270213 2025-12-19

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

164 enrolled

Neoplasm Metastasis, Neoplasms

NCT05856981 2025-12-17

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

130 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06216301 2025-12-17

LUNAR-2

Phase 3 Recruiting

734 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06108050 2025-12-16

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

177 enrolled

Neoplasm Metastasis

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT05338658 2025-12-09

Study of PAT in Patients With Solid Tumor Cancers

21 enrolled

Neoplasm Metastasis

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

DermatologicHead & NeckSarcoma

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT07021898 2025-12-03

BOREALIS-1

200 enrolled

Neoplasm Metastasis, Neoplasms

NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

36 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT06940440 2025-10-15

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

9 enrolled

Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT06983743 2025-09-11

AURORAS-1

200 enrolled

Neoplasm Metastasis, Neoplasms

NCT06831136 2025-09-10

PANCARDINAL-2

24 enrolled

Neoplasm Metastasis, Neoplasms

NCT05394103 2025-08-17

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

130 enrolled

Neoplasm Metastasis

NCT05086692 2025-07-09

ABILITY-1

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

115 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06415487 2025-07-01

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

30 enrolled

Neoplasm Metastasis

NCT05877430 2024-12-20

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

160 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma, Neoplasm Metastasis

NCT06016920 2024-12-17

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

51 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)